250 related articles for article (PubMed ID: 27254952)
1. [Role of bronchodilators in therapy for COPD-mechanisms of LABA and LAMA on airway smooth muscle].
Kume H
Nihon Rinsho; 2016 May; 74(5):813-9. PubMed ID: 27254952
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
Calzetta L; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():168-73. PubMed ID: 25981302
[TBL] [Abstract][Full Text] [Related]
3. An update on LAMA/LABA combinations for COPD.
Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis.
Aziz MIA; Tan LE; Wu DB; Pearce F; Chua GSW; Lin L; Tan PT; Ng K
Int J Chron Obstruct Pulmon Dis; 2018; 13():3203-3231. PubMed ID: 30349228
[TBL] [Abstract][Full Text] [Related]
5. Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Drug Saf; 2016 Jun; 39(6):501-8. PubMed ID: 26924197
[TBL] [Abstract][Full Text] [Related]
6. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
Montuschi P; Ciabattoni G
J Med Chem; 2015 May; 58(10):4131-64. PubMed ID: 25587755
[TBL] [Abstract][Full Text] [Related]
7. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
Cazzola M; Molimard M
Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
[TBL] [Abstract][Full Text] [Related]
8. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA.
Cohen JS; Miles MC; Donohue JF; Ohar JA
Int J Chron Obstruct Pulmon Dis; 2016; 11():785-97. PubMed ID: 27143870
[TBL] [Abstract][Full Text] [Related]
9. Research and development of bronchodilators for asthma and COPD with a focus on G protein/KCa channel linkage and β2-adrenergic intrinsic efficacy.
Kume H; Fukunaga K; Oguma T
Pharmacol Ther; 2015 Dec; 156():75-89. PubMed ID: 26432616
[TBL] [Abstract][Full Text] [Related]
10. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
12. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
Feldman GJ; Edin A
Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
[TBL] [Abstract][Full Text] [Related]
13. Bronchodilators, receptors and cross-talk: Together is better?
Panettieri RA
Postgrad Med; 2015; 127(7):771-80. PubMed ID: 26293997
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.
Cazzola M; Calzetta L; Page CP; Rogliani P; Facciolo F; Gavaldà A; Matera MG
Eur J Pharmacol; 2014 Dec; 745():135-43. PubMed ID: 25446566
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Wu J; Ye Y; Li C; Zhou W; Chang R
J Cardiovasc Pharmacol; 2019 Sep; 74(3):255-265. PubMed ID: 31306366
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
[TBL] [Abstract][Full Text] [Related]
17. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Mastrodicasa MA; Droege CA; Mulhall AM; Ernst NE; Panos RJ; Zafar MA
Expert Opin Investig Drugs; 2017 Feb; 26(2):161-174. PubMed ID: 28004591
[TBL] [Abstract][Full Text] [Related]
18. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
Babu KS; Morjaria JB
Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
[TBL] [Abstract][Full Text] [Related]
19. Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease.
Malerba M; Radaeli A; Montuschi P; Babu KS; Morjaria JB
Expert Opin Investig Drugs; 2017 Mar; 26(3):319-329. PubMed ID: 28117615
[TBL] [Abstract][Full Text] [Related]
20. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.
Rogliani P; Matera MG; Facciolo F; Page C; Cazzola M; Calzetta L
Br J Pharmacol; 2020 Mar; 177(5):1150-1163. PubMed ID: 31660611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
